斯奇康联合氯雷他定治疗小儿过敏性紫癜疗效分析  

Curative effect analysis of BCG-PSN combining with Loratadine in the treatment of anaphylactoid purpura

作　　者：窦爱燕 于鹏[1] 李琰[1] 孙含青 

机构地区：[1]山东省枣庄市妇幼保健院儿科,山东枣庄277100

出　　处：《中国现代医生》2012年第19期138-138,140,共2页China Modern Doctor

摘　　要：目的与传统方法相比较,探讨斯奇康和氯雷他定治疗过敏性紫癜的疗效。方法随机抽取40例确诊为过敏性紫癜的患儿随机分为治疗组及对照组,各20例,对照组应用传统方法治疗,治疗组在传统方法治疗的基础上口服氯雷他定5 mg,1次/d,7 d为一个疗程;斯奇康0.5 mL/次,肌注,每周2次,18针为一个疗程,并随访1年。结果治疗组治愈率为90.0%,复发率为5.0%;对照组治愈率为70%,复发率为20%。两组痊愈率及复发率比较差异有显著性,具有统计学意义(P<0.05)。结论斯奇康联合氯雷他定治疗小儿过敏性紫癜疗效显著。Objective To investigate the effect of BCG-PSN combining with Loratadine in the treatment of anaphylactoid purpura. Methods Forty patients with Anaphylactoid purpura were divided into two groups randomLy.In the treat group patients were treated with BCG-PSN combining with Loratadine. Loratadine was taken each time once a day for 7 days. BCG-PSN： 0.5 mL was taken each time twice per week for 7 weeks. And all the patients were observing for one year. Re- sults There were significant different in the two groups （P 〈 0.05）. Conclusion The effect of BCG-PSN combining with Lo- ratadine in the treatment of anaphylactoid purpura is significant.

关 键 词：过敏性紫癜 氯雷他定 斯奇康 

分 类 号：R725.6[医药卫生—儿科]